stockportfolio.pro
Amphastar Pharmaceuticals, Inc. P/E Ratio 2012–2025
Amphastar Pharmaceuticals, Inc. (AMPH) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -13.6%/yr over 13 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 13.19 | +8.7% |
| FY 2024 | 12.13 | -49.0% |
| FY 2023 | 23.79 | +47.7% |
| FY 2022 | 16.10 | -13.6% |
| FY 2021 | 18.63 | -97.2% |
| FY 2020 | 670.33 | +3305.5% |
| FY 2019 | 19.68 | — |
| FY 2018 | — | — |
| FY 2017 | 240.50 | +174.2% |
| FY 2016 | 87.71 | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
Source: Amphastar Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Amphastar Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmphastar Pharmaceuticals, Inc. — frequently asked questions
What is Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio?
Amphastar Pharmaceuticals, Inc. (AMPH) reported price-to-earnings ratio of 13.19 for fiscal year 2025, per its SEC filings.
How has Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2012 and 2025, AMPH's price-to-earnings ratio declined at roughly 13.6% per year (compound annual rate), from 87.71 to 13.19.
Where does this data come from?
Figures are computed from Amphastar Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.